DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 021055/S-010

SUPPLEMENT APPROVAL
FULFILLMENT OF POSTMARKETING COMMITMENT

Valeant Pharmaceuticals Luxembourg S.a.r.l
c/o Valeant Pharmaceuticals North America, LLC
Attention: Sean Humphrey
Manager, Regulatory Affairs
400 Somerset Corporate Boulevard
Bridgewater, NJ 08807

Dear Mr. Humphrey:

Please refer to your Supplemental New Drug Application (sNDA) dated January 24, 2015, received January 30, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Targretin® (bexarotene) Capsules, 75 mg.

We acknowledge receipt of your amendments dated March 2 and 11; and June 25, 2015.

This "Prior Approval" supplemental new drug application revises the Clinical Trials section of the prescribing information to incorporate study results from Study E7273-G000-401 entitled "*Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Patients with Refractory Cutaneous T-Cell Lymphoma*."

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insertand text for the patient package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "*SPL Standard for Content of Labeling Technical Qs and As*" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

FULFILLMENT OF POSTMARKETING COMMITMENT

We have received your submission dated January 24, 2015, containing the final report for the following postmarketing commitment listed in the December 29, 1999, approval letter.

PMC 1397-1 To conduct a randomized controlled clinical trial in patients with cutaneous T-cell lymphoma. The trial should compare three dose levels of Targretin. The Agency agrees with their proposed doses of 125, 300, and 400 mg/m^2. The primary endpoint should be tumor response according to the Physician's Global Assessment, the Composite Assessment of Index lesion Severity and the percent Body Surface Area Involment with tumor. Tumor responses must be documented with photographs of index lesions and full body photographs (front and back). Time to tumor response, time to tumor progression and tumor response duration should also be assessed. The effect on pruritis and other tumor specific symptoms should be assessed. The trial must be conducted in the same patient population for which the drug is approved. Quality of life should also be assessed. Agreed upon dates for this trial are as follows: the trial should be initiated with 3 months of protocol finalization; patient accrual should be completed 3.5 years after study initiation; the study results and analysis should be submitted to the Agency within

9 months of the date that all patients remaining on the study have been followed for a least 24 weeks. Bone mineral density testing will be conducted in a cohort of these study patients.

We have reviewed your submission and conclude that the above commitment was fulfilled.

This completes all of your postmarketing commitments acknowledged in our December 29, 1999, letter.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Tinya Sensie, Regulatory Project Manager, at (240) 402-4230.

Sincerely,

{See appended electronic signature page}

Ann T. Farrell, MD
Director
Division of Hematology Products
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ANN T FARRELL
07/29/2015